Donald A. Bergstrom - Oct 3, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as attorney-in-fact
Stock symbol
RLAY
Transactions as of
Oct 3, 2022
Transactions value $
-$146,480
Form type
4
Date filed
10/4/2022, 04:22 PM
Previous filing
Sep 29, 2022
Next filing
Nov 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $33K +8K +9.02% $4.12 96.7K Oct 3, 2022 Direct F1, F2
transaction RLAY Common Stock Sale -$179K -8K -8.27% $22.43 88.7K Oct 3, 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -8K -7.31% $0.00 101K Oct 3, 2022 Common Stock 8K $4.12 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2 Includes 78,707 shares underlying restricted stock units.
F3 This transaction was executed in multiple trades at prices ranging from $22.09 to $22.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.